Neil O'Neill Gilmore is CEO at Editas Medicine, Inc. (EDIT). They have made 11 open-market trades across 1 company since 2023, most recently 2026-09-03.
CIK 0001742084
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 11 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| EDIT | 243,189 | $666K |
| SRPT | 28,546 | $542K |
| Total | $1.2M |
Shares reported on the most recent Form 4, priced at the 2026-09-04 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EDIT | SELL | 2026-09-03 | 2026-09-04 | $3.04 | $16K | -14.6% | -11.9% | — |
| EDIT | SELL | 2026-06-03 | 2026-06-05 | $2.70 | $42K | -8.0% | +31.9% | +11.4% |
| EDIT | SELL | 2026-03-03 | 2026-03-04 | $2.02 | $11K | +16.8% | +24.1% | +29.2% |
| EDIT | SELL | 2025-12-03 | 2025-12-04 | $2.15 | $12K | +2.4% | -18.8% | -10.6% |
| EDIT | SELL | 2025-09-03 | 2025-09-04 | $2.60 | $15K | +11.0% | +49.0% | -7.3% |
| EDIT | SELL | 2025-06-03 | 2025-06-04 | $1.72 | $26K | +20.0% | +41.1% | +37.2% |
| EDIT | SELL | 2025-03-04 | 2025-03-05 | $1.71 | $28K | -26.9% | -46.6% | -5.7% |
| EDIT | SELL | 2024-12-03 | 2024-12-05 | $2.08 | $3K | -22.1% | -26.7% | +5.1% |
| EDIT | SELL | 2024-09-04 | 2024-09-06 | $3.42 | $5K | +6.6% | -11.8% | -47.5% |
| EDIT | SELL | 2024-06-04 | 2024-06-06 | $5.50 | $134K | -6.5% | -10.6% | -35.1% |
| EDIT | SELL | 2024-03-05 | 2024-03-05 | $9.42 | $1.5M | -11.7% | -26.1% | -41.3% |
| EDIT | SELL · 10b5-1 | 2023-06-05 | 2023-06-07 | $9.50 | $62K | -20.5% | -20.0% | -16.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.